The SELECT trial showed that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity and established cardiovascular disease, without requiring a diabetes diagnosis. The FLOW trial showed kidney benefits with semaglutide use in patients with type 2 diabetes and chronic kidney disease. Improvements in hard clinical outcomes like cardiac events, kidney disease, and death are commonly observed with GLP-1 use, and are due to both the direct effects of treating the obesity, and indirect effects of the medications themselves
In recent years, glutathione has become more popular in the Philippines as a supplement for whitening the skin
Genotropin (somatropin) prescribing information
The Researchers would like to thank the Deanship of Graduate Studies and Scientific Research at Qassim University for financial support (QU-APC-2025)
While these specific proteins were not significantly elevated in the sibling validation cohort, computational predictions based on (s)PLS-DA analysis did identify proteins associated with immunity and inflammatory responses such as Zinc-alpha-2-glycoprotein (AZGP1) and Carboxypeptidase B2 (CPB2) as being important contributors to group separation 48,49,50
Cys 2 ) and cystine-free (Cys 2 -free) medium with vehicle (DMSO) or ferrostatin-1 (Fer-1, 1 M)
